Jessica Pougoue Ketchemen

5PUBLICATIONS
32CO-AUTHORS
Molecular targetsPharmaceutical delivery technologiesBiomaterialsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 18, 2026
Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models.

|Dec 22, 2025
Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.

Jessica Pougoue Ketchemen, Stephen Ahenkorah, Emmanuel Nwangele

|May 28, 2025
Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering.

Olga Bednova, Jessica Pougoue Ketchemen, Hazem Mslati

|Mar 24, 2025
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.

Anjong Florence Tikum, Nikita W Henning, Jessica Pougoue Ketchemen

|Dec 13, 2024
Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.

Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker

Pageof 1

Frequent Collaborators

4 joint publications

Humphrey Fonge

3 joint publications

Fabrice Ngoh Njotu

3 joint publications

Hanan Babeker

3 joint publications

Alissar Monzer